Tag: clinical trial
-
Groundbreaking Gene Therapy Brings Hope for Child with Rare Parkinson’s Disease
Hope for a Rare Parkinson’s Disease Patient In Singapore, a medical breakthrough has sparked cautious optimism for families affected by a rare form of Parkinson’s disease that strikes in childhood. A few weeks after a Spanish girl named Irai was born, doctors noticed severe motor and developmental challenges. She could not hold her head up,…
-
Renalys Pharma Reports Positive Phase III Topline Results for Sparsentan in Japanese IgA Nephropathy Patients
Positive topline results in Japanese IgA nephropathy trial Renalys Pharma announced positive topline data from a Phase III study evaluating sparsentan in Japanese patients with IgA nephropathy (IgAN). The trial enrolled 35 participants and was designed to assess the efficacy and safety of sparsentan, a dual-acting agent targeting both the endothelin and angiotensin receptor pathways,…
-
Sparsentan Phase III IgA Nephropathy in Japan: Positive Results
Groundbreaking Phase III topline results for Sparsentan in Japanese IgA nephropathy patients Renalys Pharma has announced positive topline results from a Phase III study evaluating sparsentan in Japanese patients with IgA nephropathy. The trial, conducted in a cohort of 35 patients, focused on the primary endpoint of the percent change from baseline in the 24-hour…
-
Antibiotic resistance: how a pioneering trial is using old drugs to save babies from sepsis
New hope for newborns in a warm coastal town Just minutes from the turquoise waters of Kilifi Creek, a team of clinicians, microbiologists and technicians is rewriting how we treat neonatal sepsis. In a region where antibiotic resistance threatens to outpace medical advances, the NeoSep1 trial is testing whether familiar, older antibiotics can save vulnerable…
-
Old Drugs, New Hope: How a Pioneering Trial Uses Familiar Antibiotics to Save Babies from Sepsis
Introduction: A quiet revolution in neonatal care In a sunlit clinic near Kenya’s Kilifi Creek, a team of clinicians, microbiologists, and researchers is tackling one of medicine’s toughest challenges: sepsis in newborns. The NeoSep1 trial is testing a bold idea—using older, well-known antibiotics in new combinations to outpace resistance and improve survival for some of…
-
Paradromics FDA Approval: Brain Implant Trials Begin
Paradromics Secures FDA Permission to Move Into Human Trials Paradromics, a prominent player in the brain-computer interface (BCI) space, has received clearance from the U.S. Food and Drug Administration (FDA) to begin human trials of its next-generation brain implant. This milestone signals a key turning point for neurotechnology, as researchers and patients await data on…
-
Mazdutide 9 mg Drives Weight Loss as GLORY-2 Trial Meets Endpoints in Obese Chinese Adults
New GLORY-2 Results Highlight Mazdutide’s Potential in Obesity Management Innovent Biologics, in collaboration with partner companies, announced encouraging results from the GLORY-2 study evaluating Mazdutide 9 mg in Chinese adults with obesity. The multi-center trial reports substantial weight loss and favorable safety signals, with reductions reaching as high as 20.1% of baseline body weight for…
-
Mazdutide 9 mg Delivers Notable Weight Loss in Chinese Obesity Patients: GLORY-2 Trial Surpasses Endpoints
Breakthrough in Obesity Treatment: GLORY-2 Report Highlights Mazdutide 9 mg Innovent Biologics and collaborating partners announced compelling results from the GLORY-2 phase 3 trial evaluating Mazdutide 9 mg in adults with obesity in China. The study reports weight loss of up to 20.1% among participants, with the primary endpoint and all key secondary endpoints met.…
-
Mazdutide 9 mg Delivers Up to 20.1% Weight Loss in Chinese Adults: GLORY-2 Study Set to Shape Obesity Treatment
New GLORY-2 Results Highlight Mazdutide 9 mg’s Weight-Loss Potential Innovent Biologics and partners report compelling outcomes from the GLORY-2 trial, evaluating the investigational drug mazdutide 9 mg in Chinese adults with obesity. The study met its primary endpoint and all key secondary endpoints, underscoring mazdutide’s potential to transform obesity management in a population with high…
-
Time gene editing therapy to halve bad cholesterol: Australia leads first-in-human trial
Groundbreaking first-in-human trial unfolds in Australia Researchers in Melbourne have announced a landmark first-in-human trial of a gene-editing therapy aimed at drastically reducing harmful lipids in the blood. The study tests CTX310, a pioneering treatment designed for people with difficult-to-treat lipid disorders who struggle to control their LDL cholesterol and triglyceride levels despite standard therapies.…